Demetri Michalakis is a recognized international investor in the energy, medical research, and well-known commodities trader.
With more than 25 years of experience building and funding multibillion-dollar hedge funds and private equity firms in the United States, Europe, Hong Kong, and Middle East, accumulated a substantial portfolio of public offerings through which innovation and pioneering engineering is successfully delivered to the market through value creation. Together with his Group of Companies and associated private equity funds, Mr Michalakis accumulated capital fund structure more than USD50 billion. In addition to venture capital and private equity funding, is now focused on investments in telecommunications, wireless and satellite communications, medical science, and start-ups.
Geoff Dixon is a Member of the Board of Directors of Mentone Ltd, which is a subsidiary of Inter-M Traders.
Mr Dixon has over 35 years’ experience in executive management positions, biotech businesses and in providing consulting and technology services to the financial services industry. His management experience ranges from senior positions in large multi-national companies, to being the lead in start-up and entrepreneurial ventures.
Dr Peter Whitton is a well-respected expert in the fields of microbiology and biochemistry with over 20 years’ experience and is recognized as a leader in the field of plant cell culturing and research. Dr Whitton has a BSc in Biology and Chemistry, and a PhD in Biochemistry. He is a Member of the Institute of Biology and Chartered Biologists, a Member of the Royal Society of Chemistry, and a Fellow of the Institute of Biomedical Sciences.
Dr Whitton has a wide-ranging expertise, having provided advisory services to leading pharmaceutical companies such as GlaxoSmithKline and Boots on regulatory strategy, as well as directing research and providing toxicology advice to Pfizer. Dr Whitton previously served as Director and Chief Scientific Officer for Naturally Scientific Technologies Ltd., where he developed and patented methods to produce glyceraldehyde from CO2 and the production of Lipids using plant cell culture technologies. Prior to joining Naturally Scientific, Dr Whitton ran and managed his own research organization, Phyto-Research Ltd., for five years and secured several patents in the field of plant tissue culture and natural sciences, as well as providing research and advisory services to leading pharmaceutical companies and universities. During this period Dr Whitton worked with The Serious and Organized Crime Directorate of the Metropolitan Police with Assistant Commissioner Tarique Gaffur on the development of new drug and explosive detection techniques. Dr Whitton held the position of Senior Scientist for several years for an organization specializing in the preparation of herbal-based remedies and cosmetics, and was responsible for research, quality and conformance with British Pharmacopeia Standards and compliance with Cosmetic Safety regulations.
Dr Whitton has successfully patented many bio-technology patents with a particular focus on the use of plant cell technology for industrial applications. He was co-founder and currently serves as a Director of Lykke Research Ltd., a bio-technology company that has developed and patented a process to produce the API from the Hoodia Gordonii plant from cell cultures for use in the dietary supplements market as an appetite suppressant. He is the co-founder and a Director of PhytoCyte Pty, a bio-technology company that has developed a process to produce cannabinoids and their APIs from cell cultures for the medicinal and recreational cannabis markets.
Dr Robert Kirk is the Head of Compliance and Acquisitions, and a highly effective executive in the finance sector, having led large and small corporations to repeated success. He has exceptional abilities in finding unique funding sources and securing them for companies. When not taking charge of high-level projects, Dr Kirk supports C-level executives with valuable advice. His recommendations have consistently resulted in multi-million-dollar windfalls for partners. Specialities in analysis, strategic planning, creative insight in the execution of the plant to meet client’s needs, recruiting, and extensive network of colleagues and resources. He lives in Orlando, US, where he splits his time between work and family.
Dr Kirk has a BS Degree in Genetics, JD Degree in Law, and an OD Degree in Physiological Optics.
Petros Charalambous is one of the Directors of our Company.
He has over 15 years’ experience in the audit and assurance services, of local and international companies spread over several industries, including manufacturing, distribution, travel and tourism, construction, investing, commodity trading, non-profit organizations, and pension funds.
Mr Charalambous is a Member of the Institute of Association of Chartered Certified Accountants, and a Member of the Institute of Certified Public Accountants of Cyprus.
John Munoz is the Chairman and CEO of International Alternative Energy Corporation, a renewable energy technology and services company, with operations in Europe and Asia.
Mr Munoz has over 27 years’ experience in capital markets, and investment banking, working both on the buy-side and sell-side in transactions, including mergers, acquisitions, divestitures, spin-offs, private and public equity, and debt financings. In strategic, advisory and director roles, Mr Munoz has executed on the capital formation, analysis, restructuring, mergers and acquisitions, marketing and public market listing needs of dozens of client companies in a broad range of industries, satellite, wireless, telecommunications, healthcare, real estate, streaming radio, fintech, retail, renewable energy, film/media, oil/gas, food, and nutraceuticals.
Aristotle Michalaki is Head of Investment Relations at Inter-M Traders, is a results-driven individual with knowledge in business development, and highly organized in client relationship management. Excels in finding solutions to the potential hidden risks that may disrupt their financial plan.
Mr Michalaki has a BS in Risk Management, and a Minor in International Business from the Smeal College of the Pennsylvania State University, where he completed his studies a year early. He has an immense range of providing advisory services in a wide variety of sectors and provided financial planning to pharmaceutical and bio-medical companies, CPAs, attorneys, and government bodies. He currently holds licenses with FINRA (series 7 and series 66) and NIPR (life insurance, accident and health insurance, property insurance and casualty insurance).
Mr Michalaki’s potent blend of managerial and sales expertise demonstrate a successful track record of increasing sales and market share by establishing strong alliances with top clients and referral sources, consistently ranked among top performers in a highly competitive industry. Prior to joining Inter-M Traders, Mr Michalaki was a well-respected planner at Prudential. There he was on the President’s Council as one of the top producers in their international company. His base of duties ranged from advising individual to leading seminars for top corporations.
At Inter-M Trading Mr Michalaki leads a team in research raising funds and develops operational risk management plans. He also ensures the company is appropriately and strategically positioned with analysist, investors, and all stakeholders.